Alzinova AB
78D
Company Profile
Business description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
Contact
Entreprenorsstraket 10
GoCo House
Molndal431 53
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
ASX healthcare giant rallies despite a fall in profits
Easing investor concerns and signalling a return to growth.
stocks
Weekly earnings wrap: BHP, CSL, NAB and more
Materials, banking, healthcare and retail heavyweights reveal diverging outlooks.
stocks
Chart of the Week: Our top dividend stock picks on the ASX
Highlighting key income opportunities on the ASX.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,298.50 | 9.60 | -0.10% |
| CAC 40 | 8,454.15 | 47.76 | -0.56% |
| DAX 40 | 25,974.03 | 117.30 | -0.45% |
| Dow JONES (US) | 53,111.45 | 351.60 | -0.66% |
| FTSE 100 | 10,723.70 | 19.65 | -0.18% |
| HKSE | 25,698.49 | 203.42 | 0.80% |
| NASDAQ | 26,179.88 | 151.21 | -0.57% |
| Nikkei 225 | 66,216.79 | 890.37 | 1.36% |
| NZX 50 Index | 13,919.82 | 9.85 | -0.07% |
| S&P 500 | 7,688.53 | 19.45 | -0.25% |
| S&P/ASX 200 | 9,083.80 | 18.00 | -0.20% |
| SSE Composite Index | 3,903.72 | 9.30 | 0.24% |